The FDA has approved 9 cancer drugs that target specific mutations, regardless of which organs harbor the tumors—a growing trend that will require insurers to revise their treatment approval processes.

Genetic profiling of tumors—based on a sample from the tumor, a patient's blood, or both—can help clinicians determine if targeted therapies known to block the growth of certain types of tumors would be appropriate for specific patients.

The protein KRAS, mutated in many cancers, was deemed ‘undruggable’. Now scientists are hoping to save lives with a batch of new compounds that target it.

These mutations may happen in response to environmental or lifestyle factors, or may be passed down through family members. Genetic testing can be important in catching certain family cancers early and ensuring patients receive the right treatment for their disease.

The direct-to-consumer genetic test, approved by US regulators in 2018, examines 3 out of the more than 1,000 known breast cancer-linked genetic mutations. It looks for genetic variations that can increase risk for breast, ovarian, and other cancers. These mutations are most commonly found among Jewish people with Eastern European ancestry.

Certain gene variants can affect how quickly or slowly medications are broken down in the body, affecting drug effectiveness and the risk of drugs failing. Such testing is often not covered by insurance companies though research indicates if these tests were performed for more than six drugs across the US population, avoided ailments would likely climb into the hundreds of thousands.

The American Association for Cancer Research's "Snapshot of a Year of Progress" offers an overview of significant advancements in cancer research and treatment over the past year. Take a quick look at the rapid pace of scientific discovery and the translation of research findings into clinical practice. In 2024 alone, health regulators approved 15 new anticancer therapies alone.

While new treatments for cancer are under continuous development, researchers are increasingly using engineering principles to find wholly new strategies to combat the disease. Directions include nanoparticle drug delivery, advanced imaging tools, developing new materials to interact with cells, tissue engineering, robotic surgeries, and more. Such interdisciplinary efforts are expected to unlock new tools and therapies beyond traditional drug formulation.

The explosive growth of life sciences data is driving artificial intelligence methods to gain traction in biology and medicine — including cancer research.

Lung cancer deaths are declining faster than new cases due to advances in treatment. The progress illustrates what is possible, even for a cancer that has long had a poor prognosis.

Medicine works better when the treatments are tailored to fit each individual person’s biology and history. Homogeneous patient selection in clinical trials means treatments and care are being refined based on only a small range of variables, some of which may not apply to you. This 40-minute podcast episode discusses the historical and current reasons for the lack of clinical trial diversity and what this means for the future of personalized medicine.

This podcast interview with a Harvard Medical School professor focused on cancer genetics and prevention discusses the specifics of genetic testing and insights and the challenges of processing the outcomes of the testing and what may be actionable—or not.

Purdue University scientists are at work on a new cancer treatment that attacks immune system cells that feed and protect cancer cells rather than attacking them. The immunotherapy process promises to become a universal treatment for solid tumors. Thus far, the treatment has been tested and shown to work on human tumor cells in the laboratory and animal models.

While cancer remains incurable, there's been so much progress in its treatment over the last two decades. Nature provides an abridged history of milestones and major triumphs in cancer research and treatment. Start in the year 2000, and see how much has changed in the first quarter of the new millennium

A study shows trametinib and rapamycin, two drugs used for cancer treatment in humans, increased mouse lifespan when used together. The medications delayed the onset of cancer and reduced chronic inflammation, results that will be explored in future research.

Despite researchers' and physicians' pushback, race is still used in studies and clinics to categorize human differences in health conditions and treatment responses. This article explores how race has influenced breast cancer research. Considering race as a factor in cancer research, diagnosis, and treatment can lead to racial inequalities. Sociocultural factors, including food access and air pollution, greatly influence health outcomes.

Navigating a cancer diagnosis can be terrifying and overwhelming. There is a robust community of patient advocates dedicated to prevention and diagnosis, research and clinical trials, legislation, needs of individual cancer types, among others. See how patient advocacy improves cancer research leading to improved treatment options and patient care.

If you've ever wondered what the difference was between immunotherapy and chemotherapy, this short video takes you through the steps. Briefly, chemotherapy attacks cancer in tumor cells directly, while immunotherapy encourages your immune system to fight it. There's more to it than that, but this delightful two-and-a-half-minute video provides a good primer.

The immune system detects and destroys abnormal cells, curbing the growth of many cancers. Immunotherapy works to boost the body’s immune system to target and kill cancer cells. There are many ways to accomplish this, including adaptive cell therapy, checkpoint inhibitors, vaccines, and monoclonal antibodies.

KJ Muldoon had a 50% chance of surviving a genetic mutation until doctors developed a one-of-a-kind gene-editing therapy. In an interview with one of the researchers behind the treatment, learn what it will take to make personalized genetic medicine possible for everyone.

Cancer rates are rising among Gen X and Millennials, with more cancer diagnoses being made in their 30s and 40s than previous generations. Factors such as prenatal exposures, environmental toxins, and lifestyle choices may contribute to this trend. Memorial Sloan Kettering Cancer Center's experts discuss these issues, exploring how these insights could reshape cancer risk understanding.

Medical robots are on the verge of being able to be injected into the body, where they will be responsible for semi-autonomous behavior, such as detecting cancer cells and distributing medication. This six-minute video dives into the science of these nanorobots, which are smaller than blood cells. Applications of these nanobots could range from disease discovery and condition monitoring to tissue repair and artificial blood delivery.

The Cancer Research Institute takes a close look at immunotherapy and its potential for treating cancer. Immunotherapy teaches the patient's own immune system to recognize and fight cancer cells. It's especially promising as an alternative for cancers that resist chemotherapy and radiation treatment. Have all your questions about the process and its promise here.

The UK's National Health Service has launched a trial for a blood test that can detect a dozen types of cancers with just ten drops of blood. An AI tool looks for genetic material known to be released by tumors, allowing for cancer detection before tumors are large enough to be imaged.

The therapy, originally targeting cancer, involves taking a patient's own T cells, genetically reprogramming them to recognize and attack a specific target and then infusing them back into patients. For autoimmune diseases, the therapy instead programs them to target immune cells that are causing problems, restoring immune system tolerance.

As the medical sector moves toward more personalized care, healthcare systems are using technologies such as artificial intelligence (AI) and data analytics to pave the way for precision medicine. This analysis in HealthTech Magazine looks into the...

The Dana-Farber Cancer Institute provides a delightful Science Illustrated animation explaining PD-1/PD-L1 immunotherapy and how it fights cancer. Briefly, the treatment helps T-cells recognize cancerous cells that would ordinarily be "disguised" by proteins and attack. The fight is made more fair and effective by immunotherapy and similar cancer treatments.

An outline of the discovery of imatinib (Gleevec), a ground-breaking drug that transformed the treatment of chronic myelogenous leukemia and sparked the beginning of precision medicine.

A primer on genetic testing, personalized medicine, and the promise of pharmacogenomics–the use of genetics to predict an individual's response to a drug.

Scientists have developed a tool to evaluate the risk of lung cancer, the most deadly form of the disease. Named "Sybil," this AI program was trained using CT scans with clear cancer signs, followed by scans where cancer wasn’t obvious. The tool is able to review CT scan data to predict a patient's of developing a lung cancer within six years. See how it works here.

The agency proposed a new rule in 2023 to make it explicit that these types of tests are devices under existing law and clarify that that the agency could move to regulate them. They finalized a regulatory change in 2024 that added the words "including when the manufacturer of these products is a laboratory" to an existing law, but a federal district court vacated that edit in March 2025—returning the law to as it was before.